Competitive Generic Therapies Get Help With Development, But Not Goal Date

Draft guidance says US FDA will try to expedite assessment of competitive generic therapy designees, but will not give shorter review goals.

old chronometer
Sponsors will not automatically receive a priority assessment upon gaining a competitive generic therapy designation.

More from Generics

More from Biosimilars & Generics